According to a recent regulatory filing, Moderna indicated there was a possibility it was not the first company to make "inventions claimed" in its patent applications, including those for its experimental coronavirus vaccine mRNA-1273, as reported in This is Money.
"For this and other reasons, we may be unable to secure desired patent rights, thereby losing exclusivity," the company stated.
The statement was made in a quarterly filing on August 6 under mandatory disclosures of risks to its business, whereas prior quarterly filings with US regulators did not have the disclosure, the news source said.
In July, it lost a bid to invalidate a US patent owned by Arbutus Biopharma that poses a potential obstacle to Moderna's efforts to develop next-generation vaccines.
To read more NewsPoints articles, click here.